SCHEMBL1366355 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	HDAC6	Q9UBN7	1/20	0.38

▸	LIMK1	P53667	2/20	0.34

▸	GRM5	P41594	4/20	0.33

▸	RAF1	P04049	3/20	0.33

▸	BRAF	P15056	3/20	0.33

▸	L3MBTL1	Q9Y468	1/20	0.32

▸	ACKR3	P25106	1/20	0.32

▸	PDE10A	Q9Y233	2/20	0.31

▸	PDE2A	O00408	1/20	0.31

▸	NPC1	O15118	1/20	0.31

▸	TP53	P04637	1/20	0.31

▸	GAA	P10253	1/20	0.31

▸	MAPK1	P28482	1/20	0.31

▸	RAB9A	P51151	1/20	0.31

▸	SMN1; SMN2	Q16637	1/20	0.31

▸	CTSA	P10619	1/20	0.31

▸	TGFBR1	P36897	1/20	0.30

▸	AXL	P30530	1/20	0.30

▸	FLT3	P36888	1/20	0.30

▸	MERTK	Q12866	1/20	0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL1369376	0.81	HDAC6 (0.38)	HDAC6LIMK1GRM5RAF1BRAF
SCHEMBL12144198	0.81	KDR (0.40)	HDAC6LIMK1RAF1BRAFL3MBTL1
SCHEMBL12144153	0.81	LIMK1 (0.41)	HDAC6LIMK1RAF1BRAFMAPK14
SCHEMBL12144200	0.81	LIMK1 (0.58)	HDAC6LIMK1MAPK14
SCHEMBL12144176	0.80	MAPK14 (0.46)	HDAC6LIMK1RAF1BRAFMAPK14
SCHEMBL1368449	0.79	HDAC6 (0.36)	HDAC6LIMK1RAF1BRAFL3MBTL1
SCHEMBL12144152	0.79	MAPK14 (0.42)	HDAC6LIMK1RAF1BRAFMAPK14
SCHEMBL12144191	0.79	LIMK1 (0.46)	HDAC6LIMK1MAPK1MAPK14CLK4
SCHEMBL12144189	0.77	LIMK1 (0.46)	HDAC6LIMK1MAPK14
SCHEMBL12144197	0.77	LIMK1 (0.46)	HDAC6LIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-2300466-B1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL MYERS SQUIBB CO (US)	2014-08-06	—	—	EP	disclosed
US-8410128-B2	Triazolopyridine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2013-04-02	—	—	US	disclosed
US-8410128-B2	Triazolopyridine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2013-04-02	—	—	US	disclosed
US-8410128-B2	Triazolopyridine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2013-04-02	—	—	US	disclosed
US-8338604-B2	Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2012-12-25	—	—	US	disclosed
US-8338604-B2	Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2012-12-25	—	—	US	disclosed
US-8338604-B2	Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors	BRISTOL-MYERS SQUIBB COMPANY (US)	2012-12-25	—	—	US	disclosed
US-20110288085-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY	2011-11-24	—	—	US	disclosed
US-20110288085-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY	2011-11-24	—	—	US	disclosed
US-20110288085-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY	2011-11-24	—	—	US	disclosed
EP-2307411-A1	TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	Bristol-Myers Squibb Company (US)	2011-04-13	—	—	EP	disclosed
US-20110077243-A1	Triazolopyridine Compounds Useful As Kinase Inhibitors	BRISTOL-MYERS SQUIBB COMPANY	2011-03-31	—	—	US	disclosed
US-20110077243-A1	Triazolopyridine Compounds Useful As Kinase Inhibitors	BRISTOL-MYERS SQUIBB COMPANY	2011-03-31	—	—	US	disclosed
US-20110077243-A1	Triazolopyridine Compounds Useful As Kinase Inhibitors	BRISTOL-MYERS SQUIBB COMPANY	2011-03-31	—	—	US	disclosed
EP-2300466-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	Bristol-Myers Squibb Company (US)	2011-03-30	—	—	EP	disclosed
WO-2009155389-A1	TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2009-12-23	—	—	WO	disclosed
WO-2009155388-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2009-12-23	—	—	WO	disclosed
WO-2009155388-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2009-12-23	—	—	WO	disclosed
WO-2009155389-A1	TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS	BRISTOL-MYERS SQUIBB COMPANY (US)	2009-12-23	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110077243-A1	Triazolopyridine Compounds Useful As Kinase Inhibitors	MAP3K1, MAP3K5, MAP3K8	HDAC6 836/4885LIMK1 726/4885GRM5 1671/4885
US-20110288085-A1	IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS	MAP4K2, MAPKAPK2, MAP3K5	HDAC6 531/4885LIMK1 858/4885GRM5 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.